<DOC>
	<DOCNO>NCT01020838</DOCNO>
	<brief_summary>To determine sensitivity specificity visual assessment tracer uptake Florbetaben PET image compare histological verification presence absence cerebral β-amyloid respective histopathologic post mortem specimens standard truth</brief_summary>
	<brief_title>Phase III Study Florbetaben ( BAY94-9172 ) PET Imaging Detection/Exclusion Cerebral β-amyloid Compared Histopathology</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Females , childbearing potential negative urine pregnancy test day BAY949172 injection Exhibits visual , auditory , communicative capability adequate provide inform consent assent comply study procedure Is willing able lie magnetic resonance imaging ( MRI ) positron emission tomography ( PET ) scanner Is willing donate brain postmortem examination case death The subject , subject and/or legally acceptable representative compliant high probability complete study opinion investigator Has fully inform study , include provision Health Insurance Portability Accountability Act ( HIPAA ) , applicable , informed consent assent sign date ( time ) subject and/or subject 's legally acceptable representative The subject participate previous florbetaben study e.g . study 311741 may include present study . The MRI florbetaben PET scan need repeat scan perform within twelve month prior inclusion . Has severe cerebral macrovascular ( ie , multistroke ) disease brain tumor ( metastasis/brain cancer ) verify MRI Has contraindication magnetic resonance imaging ( MRI ) examination , eg , metal implant phobia determine onsite radiologist perform scan Has previously enrol study participate clinical study involve investigational pharmaceutical product within 30 day prior screen and/or administer radiopharmaceutical within 10 radioactive halflives prior study drug administration study Has severe cardiovascular instability require intensive care surveillance and/or therapeutic intervention ( i.e . catecholamine infusion )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Florbetaben</keyword>
	<keyword>Amyloid beta-protein</keyword>
	<keyword>Alzheimer 's disease</keyword>
</DOC>